The news: Eli Lilly is adding tools to its D2C platform that connect Alzheimer’s patients with virtual care and other resources.
Catch up quick: The drugmaker’s D2C website, LillyDirect, lets patients select telehealth providers treating certain disease states (e.g., obesity, migraines) who can prescribe Eli Lilly’s medications. LillyDirect also serves as an online pharmacy, delivering its medications to patients’ homes.
Here’s what’s new: Lilly’s recently FDA-approved Alzheimer’s infusion treatment, Kisunla, can’t be received via virtual care or through an online pharmacy like other conditions supported by LillyDIrect.